Fluticasone Propionate
Grundinformationen
- CAS
192191-51-8- Standard-SMILES
CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C- InChIKey
WMWTYOKRWGGJOA-CENSZEJFSA-N- Summenformel
- C25H31F3O5S
- Durchschnittliche Molmasse
- 500,6 g/mol
Überblick
Fluticasone Propionate can cause developmental toxicity according to state or federal government labeling requirements.
Namen und Bezeichner
- Bevorzugter Name
- Fluticasone Propionate
- IUPAC
- [(6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-17-(fluoromethylsulfanylcarbonyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate
- Englischer Name
- Fluticasone Impurity 5
- Summenformel
- C49H60F4O10S2
- Molmasse
- 949.12
Namen und Synonyme
FLUTICASONE PROPIONATE80474-14-2FloventCutivateFlixotideFlonaseFlovent HFAFlovent DiskusFlovent Diskus 50Flovent Diskus 100Flovent Diskus 250Xhance
Weitere Namen anzeigen
Fluticasone Impurity 5Fluticasone Propionate-CH2 DimerFluticasone Propionate Impurity 24Androsta-1,4-diene-17-carbothioic acid, 6,9-difluoro-11-hydroxy-16-methyl-3-oxo-17-(1-oxopropoxy)-, S,S′-methylene ester, (6α,11β,16α,17α)-(6′α,11′β,16′α,17′α)-6α,11β,16α,17α)-(6'α,11'β,16'α,17'α)-6,9-Difluoro-11-hydroxy-16-methyl-3-oxo-17-(1-oxopropoxy)-,S,S’-methylene ester, (9CI) androsta-1,4-diene-17-carbothioic acidAndrosta-1,4-diene-17-carbothioic acid, 6,9-difluoro-11-hydroxy-16-methyl-3-oxo-17-(1-oxopropoxy)-, S,S'-methylene ester, (6α,11β,16α,17α)-(6'α,11'β,16'α,17'α)- (9CI)(6S,6''S,8S,8''S,9R,9''R,10S,10''S,11S,11''S,13S,13''S,14S,14''S,16R,16''R,17R,17''R)-((Methylenebis(sulfanediyl))bis(carbonyl))bis(6,9-difluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthrene-17,17-diyl) Dipropionate
Eigenschaften
Berechnete Struktureigenschaften
- XLogP
- 4
- Polarare Oberfläche (TPSA)
- 106 Ų
- H-Brücken-Donoren
- 1
- H-Brücken-Akzeptoren
- 9
- Frei drehbare Bindungen
- 6
- Schwere Atome
- 34
- Formalladung
- 0
- Komplexität
- 984
Experimentelle und physikochemische Eigenschaften
Drugs
Pharmaceuticals -> Dermatologicals -> Corticosteroids, dermatological preparations
Pharmaceuticals -> Listed in ZINC15
SolubilityInsoluble
Human Drugs
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
Pharmaceuticals
Endocrine DisruptorsPotential endocrine disrupting compound
Melting Point261-273 °C
Physical DescriptionSolid
Physikochemische Eigenschaften
- Siedepunkt
- 892.6 · 892.6±65.0 °C(Predicted)
- Dichte
- 1.37 · 1.37±0.1 g/cm3(Predicted)
- pka
- 12.23 · 12.23±0.70(Predicted)
Sicherheit und Regulatorisches
Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
GHS-Klassifizierung
GHS Classification
This chemical does not meet GHS hazard criteria for 10% (2 of 20) of reports.
Danger
H302 (20%): Harmful if swallowed [Warning Acute toxicity, oral]
P203, P233, P260, P261, P264, P270, P271, P272, P273, P280, P284, P301+P317, P302+P352, P304+P340, P318, P319, P321, P330, P333+P317, P342+P316, P362+P364, P391, P403, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 20 reports by companies from 17 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Gefahrenhinweise
Regulatory Information
Hazard Traits - Developmental Toxicity
Fluticasone propionate: Does not have an individual approval but may be used under an appropriate group standard
Hazard Classes and CategoriesAcute Tox. 4 (20%)
Chemie und Industrie
Pharmakologische Informationen
Protein BindingFluticasone propionate is 99% protein bound in serum. Topical fluticasone propionate is only 91% protein bound in serum however.
PharmacodynamicsSystemically, fluticasone propionate activates glucocorticoid receptors, and inhibits lung eosinophilia in rats. Fluticasone propionate as a topical formulation is also associated with vasoconstriction in the skin.
Mechanism of ActionFluticasone propionate works through an unknown mechanism to affect the action of various cell types and mediators of inflammation. Fluticasone propionate activates glucocorticoid receptors and inhibits lung eosinophilia in rats.
Biological Half-Life7.8 hours for intravenous fluticasone propionate. A study of 24 healthy Caucasian males shows a half life of 14.0 hours following intravenous administration and 10.8 hours following inhalation.
Metabolism/MetabolitesFluticasone propionate is cleared from hepatic metabolism by cytochrome P450 3A4. Fluticasone propionate is hydrolysed at the FIVE-S-fluoromethyl carbothioate group, forming an inactive metabolite.
FDA Pharmacological Classification
FLUTICASONE PROPIONATE
Corticosteroid Hormone Receptor Agonists [MoA]; Corticosteroid [EPC]
ALLERGY RELIEF NASAL
Corticosteroid Hormone Receptor Agonists [MoA]; Corticosteroid [EPC]
FLUTICASONE PROPIONATE NASAL
Corticosteroid Hormone Receptor Agonists [MoA]; Corticosteroid [EPC]
MeSH Pharmacological Classification
Substances that reduce or suppress INFLAMMATION.
Agents that cause an increase in the expansion of a bronchus or bronchial tubes.
Drugs used to treat or prevent skin disorders or for the routine care of skin.
Agents that are used to treat allergic reactions. Most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells. (From AMA Drug Evaluations Annual, 1994, p475)
Anbieter
Wird geladen…
Öffentliche Anfragen
Wird geladen…
Zugehörige Reaktionen
0
Keine Reaktionsaufzeichnungen unter den aktuellen Filterkriterien.
Notizen zur Verbindung
Wird geladen…